Los Angeles - 
(NewMediaWire) - November 8, 2021 - The
Schall Law Firm, a national shareholder rights litigation firm, announces that
it is investigating claims on behalf of investors of Novavax, Inc. (“Novavax” or “the Company”) (NASDAQ: NVAX) for violations of the securities laws.
The investigation
focuses on whether the Company issued false and/or misleading statements and/or
failed to disclose information pertinent to investors. Novavax is the subject
of an article published by Politico on October 19, 2021, titled: “‘They
Rushed the Process’: Vaccine Maker’s woes hamper global inoculation campaign.”
According to the article, “manufacturing problems are jeopardizing billions of
doses earmarked for poor and middle-income countries.” The article continues, “although
Novavax recently attested to some of its analytics and testing issues … the
company’s issues are more concerning than previously understood, according to
two of the people with direct knowledge of the matter.” Based on this news,
shares of Novavax traded down sharply on October 20, 2021.
If
you are a shareholder who suffered a loss, click here to participate.
We
also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East,
Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights
free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The
class in this case has not yet been certified, and until certification occurs,
you are not represented by an attorney. If you choose to take no action, you
can remain an absent class member.
The
Schall Law Firm represents investors around the world and specializes in
securities class action lawsuits and shareholder rights litigation.
This
press release may be considered Attorney Advertising in some jurisdictions
under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
